title: [Screening pelvic tumours for hereditary risk of ovarian neoplasms, a cancer center experience].
abstract: As part of a study in the North of France for screening pelvic tumours with plasma proteomic analysis, we included 82 women with hereditary risk of ovarian cancer. We report here the consequences of organized screening with usual tests. CA 125 sampling and a transvaginal pelvic ultrasound by a radiologist were systematically conducted every 6 months. Seventy-two patients were eventually evaluable. Two incident cases of peritoneal carcinomatosis (FIGO IIIB, malignant epithelial serous high-grade tumors) were discovered in two asymptomatic women with a deleterous BRCA1 mutation (2.7%). We did not observe any other primary cancer cases but an ovarian metastasis of a breast cancer. Forty women went off the study: 32 had a prophylactic bilateral salpingo-oophorectomy. Consistent with the literature, biannual screening tests combining CA125 and pelvis ultrasound is ineffective for early detection of a pelvic tumor of tubal or ovarian origin. Testing for BRCA1 or BRCA2 deleterious mutations is then crucial for suspected family syndromes of breast and ovarian cancer. For women carrying a deleterous mutation on BRCA1/2 a salpingo-oophorectomy is the only way, only the time of this surgery is debatable.
authors.affiliation: Centre Oscar-Lambret, département d'imagerie médicale, Lille, France. s-taieb@o-lambret.fr
authors.forename: Sophie
authors.initials: S
authors.lastname: Taïeb
authors.forename: Nathalie
authors.initials: N
authors.lastname: Rocourt
authors.forename: Fabrice
authors.initials: F
authors.lastname: Narducci
authors.forename: Eric
authors.initials: E
authors.lastname: Leblanc
authors.forename: Claude
authors.initials: C
authors.lastname: Adenis
authors.forename: Charles
authors.initials: C
authors.lastname: Fournier
authors.forename: Philippe
authors.initials: P
authors.lastname: Doutrelant
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Peyrat
authors.forename: Philippe
authors.initials: P
authors.lastname: Vennin
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000473:pathology; D018394:CA-125 Antigen / Q000097:blood*; D002277:Carcinoma / Q000175:diagnosis; D055088:Early Detection of Cancer / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D005602:France; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D033162:Incidental Findings; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000235:genetics / Q000601:surgery; D010386:Pelvic Neoplasms / Q000175:diagnosis; D010534:Peritoneal Neoplasms / Q000175:diagnosis; D011159:Population Surveillance / Q000379:methods; D040901:Proteomics / Q000379:methods; D014463:Ultrasonography
chemical_list: D018394:CA-125 Antigen